NCT04313322

Treatment of COVID-19 Patients Using Wharton's Jelly-Mesenchymal Stem Cells

• Status: Unknown
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 5 (estimated)
• Sponsor: Stem Cells Arabia · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Accepted

Summary

The purpose of this study is to investigate the potential use of Wharton's Jelly Mesenchymal stem cells (WJ-MSCs) for treatment of patient diagnosed with Corona Virus SARS-CoV-2 infection, and showing symptoms of COVID-19.

Detailed description

COVID-19 is a condition caused by infection with Coronoa Virus (SARS-CoV-2). This virus has a high transmission rate and is spreading at very high rates. causing a worldwide pandemic. Patients diagnosed with COVID-19 and confirmed positive with the virus, will be given three IV doses of WJ-MSCs consisting of 1X10e6/kg. The three doses will be 3 days apart form each other. Patients will be followed up for a period of three weeks to assess the severity of the condition and measure the viral titers.

Conditions

• Use of Stem Cells for COVID-19 Treatment

Interventions

Type	Name	Description
BIOLOGICAL	WJ-MSCs	WJ-MSCs will be derived from cord tissue of newborns, screened for HIV1/2, HBV, HCV, CMV, Mycoplasma, and cultured to enrich for MSCs. WJ-MSCs will be counted and suspended in 25 ml of Saline solution containing 0.5% human serum Albumin, and will be given to patient intravenously.

Timeline

• Start date: 2020-03-16
• Primary completion: 2020-06-30
• Completion: 2020-09-30
• First posted: 2020-03-18
• Last updated: 2020-03-18

Locations

1 site across 1 country: Jordan